JP2024015120A5 - - Google Patents

Download PDF

Info

Publication number
JP2024015120A5
JP2024015120A5 JP2023202765A JP2023202765A JP2024015120A5 JP 2024015120 A5 JP2024015120 A5 JP 2024015120A5 JP 2023202765 A JP2023202765 A JP 2023202765A JP 2023202765 A JP2023202765 A JP 2023202765A JP 2024015120 A5 JP2024015120 A5 JP 2024015120A5
Authority
JP
Japan
Prior art keywords
plinabulin
hours
administration
administering
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023202765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024015120A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/015867 external-priority patent/WO2019152530A1/en
Application filed filed Critical
Publication of JP2024015120A publication Critical patent/JP2024015120A/ja
Publication of JP2024015120A5 publication Critical patent/JP2024015120A5/ja
Pending legal-status Critical Current

Links

JP2023202765A 2018-02-01 2023-11-30 プリナブリンおよびg-csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 Pending JP2024015120A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862625290P 2018-02-01 2018-02-01
US62/625,290 2018-02-01
US201862713486P 2018-08-01 2018-08-01
US62/713,486 2018-08-01
US201862749060P 2018-10-22 2018-10-22
US62/749,060 2018-10-22
US201862757648P 2018-11-08 2018-11-08
US62/757,648 2018-11-08
PCT/US2019/015867 WO2019152530A1 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
JP2020541924A JP2021512121A (ja) 2018-02-01 2019-01-30 プリナブリンおよびg−csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020541924A Division JP2021512121A (ja) 2018-02-01 2019-01-30 プリナブリンおよびg−csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2024015120A JP2024015120A (ja) 2024-02-01
JP2024015120A5 true JP2024015120A5 (enExample) 2024-05-27

Family

ID=67479904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541924A Pending JP2021512121A (ja) 2018-02-01 2019-01-30 プリナブリンおよびg−csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
JP2023202765A Pending JP2024015120A (ja) 2018-02-01 2023-11-30 プリナブリンおよびg-csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020541924A Pending JP2021512121A (ja) 2018-02-01 2019-01-30 プリナブリンおよびg−csf製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法

Country Status (11)

Country Link
US (1) US20210030843A1 (enExample)
EP (1) EP3746076A4 (enExample)
JP (2) JP2021512121A (enExample)
KR (1) KR20200116477A (enExample)
CN (1) CN112105363A (enExample)
AU (1) AU2019216305B2 (enExample)
BR (1) BR112020015758A2 (enExample)
CA (1) CA3089391A1 (enExample)
IL (1) IL276197A (enExample)
SG (1) SG11202006990TA (enExample)
WO (1) WO2019152530A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
DK3334726T3 (da) 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
KR20220110747A (ko) * 2019-12-05 2022-08-09 한미약품 주식회사 화학 요법 또는 방사선 요법으로 유도된 호중구감소증을 치료하는 방법
WO2022015710A1 (en) * 2020-07-17 2022-01-20 Spectrum Pharmaceuticals, Inc. Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749786A1 (en) * 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
RU2662298C2 (ru) * 2013-10-11 2018-07-25 Бьёндспринг Инк. Лечение рака комбинацией плинабулина и таксана
SG11201810872UA (en) * 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN110381938A (zh) * 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法

Similar Documents

Publication Publication Date Title
JP2024015120A5 (enExample)
Livingston et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study
JP2020514412A5 (enExample)
JP2017516802A5 (enExample)
JP2020516646A5 (enExample)
JPWO2019152530A5 (enExample)
CA2435921A1 (en) Method of cancer therapy
Lee et al. A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer
CN102861024B (zh) Gypensapogenin A在升高白细胞的药物中的应用
CN118845664A (zh) 盐酸米托蒽醌脂质体在治疗骨与软组织肉瘤中的用途
RU2010139840A (ru) Комбинация противораковых агентов
CN113893279B (zh) 一清颗粒与环磷酰胺联合用药在抗肿瘤治疗药物中的应用
CN111388665B (zh) 一种治疗肿瘤的复合物及其制剂和用途
CN105769849B (zh) 一种治疗卵巢癌的药物组合物
Wolf Dose intensive chemotherapy in small cell lung cancer
CN117883432B (zh) 丹酚酸b的新用途
CN115120671B (zh) 一种治疗缓慢性心律失常的中药组合物及其应用
US20240307484A1 (en) Method for treating triple-negative breast cancer or metastasis thereof with pharmaceutical composition
CN102872043B (zh) Gypensapogenin B在升高白细胞的药物中的应用
Natale Chemotherapy in small cell lung cancer: the current state of the art
CN103860561B (zh) 一种防治乳腺癌的药物组合物及其应用
Choy et al. Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer
JPWO2020112765A5 (enExample)
CN116947942A (zh) 一类单萜化合物用于结直肠肿瘤治疗的用途
CN114699492A (zh) 肺力咳与环磷酰胺联合用药在制备治疗乳腺癌的产品中的应用